vimarsana.com
Home
Live Updates
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD : comparemela.com
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD
First patients dosed in...
Related Keywords
United States ,
Japan ,
New York ,
China ,
Netherlands ,
Smeeth ,
Kent ,
United Kingdom ,
Cambridge ,
Cambridgeshire ,
Americans ,
Fernando Martinez ,
Sharon Barr ,
Formoterol Fumarate ,
European Respiratory Society Congress ,
National Heart ,
Division Of Pulmonary ,
Global Initiative On Obstructive Lung Disease ,
Blood Institute ,
Centers For Disease ,
Astrazeneca ,
Global Initiative For Chronic Obstructive Lung Disease ,
International Investigator ,
Data Network ,
Harvard Medical School ,
Critical Care Medicine ,
Weill Cornell Medicine ,
New York Presbyterian Hospital ,
International Co Ordinating Investigator ,
Associate Physician ,
Executive Vice President ,
Important Safety ,
Astrazeneca Biopharmaceuticals ,
Rare Diseases ,
Study Evaluating ,
Formoterol Fumarate Metered Dosed Inhaler ,
Cardiopulmonary Outcomes ,
Chronic Obstructive Pulmonary Disease ,
Metered Dose Inhaler ,
Exercise Parameters ,
Eur Respir ,
Post Hoc Cohort Analysis ,
Respir Crit Care Med ,
Future Risk ,
United Kingdom Routine Health Care Data ,
Intj Chron Obstruct Pulmon ,
General Practice Based Population ,
Chronic Obstructive Pulmonary ,
Obstructive Lung Disease ,
Atherosclerosis Risk ,
Global Initiative ,
Chronic Obstructive Lung Disease ,
Disease Control ,
Leading Causes ,
comparemela.com © 2020. All Rights Reserved.